Trial reportAnnals of nuclear medicine2025
Radiolabelled anti-PD-L1 peptide PET/CT in predicting the efficacy of neoadjuvant immunotherapy combined with chemotherapy in resectable non-small cell lung cancer.
Trial report in Annals of nuclear medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04304066 (Research for the Molecular Imaging of the PD-L1 Targeting Tracer), which is not on this map. Cited by 8 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Research for the Molecular Imaging of the PD-L1 Targeting Tracer
Who cites it
8 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Diagnostic performance of 18F-FDG PET/CT metabolic parameters for early prediction of pathological response in NSCLC treated with neoadjuvant immuno(chemo)therapy: A systematic review and meta-analysis.European journal of nuclear medicine and molecular imaging · 2026Pooled it
- Comparison of pre-treatmentEuropean radiology · 2026Article
- Specific PET Imaging for Precision Management of Lung Cancer: Advances, Clinical Translation and Future Directions.Chemical & biomedical imaging · 2026Review
- PD-L1-targeted PET imaging for non-invasive assessment of immunotherapy response in lung cancer.Journal for immunotherapy of cancer · 2026Article
- Development of a Peptide-Based Photoimmunotherapy Drug Targeting PD-L1.Molecules (Basel, Switzerland) · 2026Article
- The role of the tumor microenvironment in mediating radiopharmaceutical therapy: bridging nuclear medicine and cancer immunotherapy.Military Medical Research · 2026Review
- Radionuclide theranostics: advances and clinical applications in lung cancer.Frontiers in oncology · 2026Review
- Structure-activity relationship ofEJNMMI radiopharmacy and chemistry · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundThis study aimed to evaluate the predictive value of baseline PD-L1 targeted peptide
methodsPatients with resectable NSCLC (n = 20) enrolled in this prospective study received baseline paired
resultsAmong 20 patients, 17 patients underwent surgery, 10 achieved an MPR and 7 did not. The SUV
conclusionBaseline
trial registrationNCT04304066, registered 13 November 2020, https://register. CLINICALTRIALS: gov/prs/app/action/SelectProtocol?sid=S000AEI9&selectaction=Edit&uid=U000503E&ts=2&cx=-awajet .
Indexed as
Identifiers
39673015What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.